Dextrometorfano* e seus sais
ANVISA lists this substance among materials that may not be used in personal-hygiene products, cosmetics or perfumes in Brazil.
Décision réglementaire et conditions complètes
- Statut
- Prohibited
- Rôle juridique
- Binding rule
- Résumé réglementaire
- ANVISA lists this substance among materials that may not be used in personal-hygiene products, cosmetics or perfumes in Brazil.
- Conditions et restrictions
Dextrometorfano* e seus sais
Identité de la substance
- Nom dans la source officielle
- Dextrometorfano* e seus sais
- CAS
- 125-71-3
- EC
- 204-752-2
- Correspondance d’identité
- standalone:official_anvisa_record
Aperçu multi-marchés pour cette identité
Fiches exactes associées actuellement présentes sur ce site. L’absence d’un marché signifie qu’aucune correspondance exacte n’a été importée, et non une autorisation d’utiliser la substance.
European Union
1 fiche associée
Ouvrir la fiche justificativeGreat Britain
1 fiche associée
Ouvrir la fiche justificativeCanada
1 fiche associée
Ouvrir la fiche justificativeNew Zealand
1 fiche associée
Ouvrir la fiche justificativeASEAN
1 fiche associée
Ouvrir la fiche justificativeChina
1 fiche associée · 1 avec conditions spécifiques
Ouvrir la fiche justificativeSouth Korea
1 fiche associée · 1 avec conditions spécifiques
Ouvrir la fiche justificativeBrazil
Fiche actuelle1 fiche associée · 1 avec conditions spécifiques
Ouvrir la fiche justificativeIndia
1 fiche associée · 1 avec conditions spécifiques
Ouvrir la fiche justificativeSaudi Arabia
1 fiche associée
Ouvrir la fiche justificative
Chimie vérifiée pour le CAS 125-71-3
Dextromethorphan
Dextromethorphan is a 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough. It has a role as a oneirogen, a xenobiotic, a prodrug, a neurotoxin, an antitussive, a NMDA receptor antagonist and an environmental contaminant. It is functionally related to a dextrorphan. It is an enantiomer of a levomethorphan. — ChEBI
- Nom IUPAC
- (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
- Formule moléculaire
- C18H25NO
- Masse moléculaire
- 271.4 g/mol
- Masse exacte
- 271.193614421 Da
- Masse monoisotopique
- 271.193614421 Da
- XLogP3
- 3,4
- Surface polaire topologique
- 12,5 Ų
- Complexité moléculaire
- 370,0
- Charge formelle
- 0
- Donneurs de liaisons hydrogène
- 0
- Accepteurs de liaisons hydrogène
- 2
- Liaisons rotatives
- 1
- Atomes lourds
- 20
- Unités covalentes
- 1
Noms et synonymes signalés à PubChem
16 autres noms signalés
Identifiants de bases de données externes
- ChEBI:CHEBI:4470
- ChEBI:CHEBI:92579
- ChEMBL:CHEMBL52440
- EPA DTXSID:DTXSID3022908
- PubMed:22608604
- PubMed:22073096
- PubMed:22066053
- PubMed:22044595
- PubMed:21973086
- PubMed:21867562
- PubMed:21614312
- PubMed:21445282
- PubMed:21436715
- PubMed:21266064
- PubMed:21244712
- PubMed:21175434
Statistiques de structure avancées
- Stéréocentres atomiques définis
- 3
- Stéréocentres atomiques non définis
- 0
- Stéréocentres de liaison définis
- 0
- Stéréocentres de liaison non définis
- 0
- Caractéristiques pharmacophoriques 3D
- 6
- Cycles 3D
- 4
- Groupes hydrophobes 3D
- 0
- Caractéristiques d’accepteur 3D
- 1
- Caractéristiques de donneur 3D
- 0
- Centres anioniques 3D
- 0
- Centres cationiques 3D
- 1
- Conformères 3D
- 2
- Rotors 3D effectifs
- 2,6
Identifiants de structure lisibles par machine
- SMILES
CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC- InChI
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1- InChIKey
MKXZASYAUGDDCJ-NJAFHUGGSA-N
Preuves issues de bases de données scientifiques complémentaires
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Color/Form: White to slightly yellow crystalline powder Source: Hazardous Substances Data Bank (HSDB)
- Melting Point: 122-124 Source: DrugBank
- Melting Point: 109-111 °C Source: Hazardous Substances Data Bank (HSDB)
- Odor: Odorless Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 1.5 g/100 mL Source: DrugBank
- Solubility: Practically insoluble in water Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Freely soluble in chloroform Source: Hazardous Substances Data Bank (HSDB)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). Source: Toxin and Toxin Target Database (T3DB)
- Exposure Routes: Oral, rapidly absorbed from the gastrointestinal tract. Source: Toxin and Toxin Target Database (T3DB)
- Note: This chemical does not meet GHS hazard criteria for 46.8% (36 of 77) of reports. Source: European Chemicals Agency (ECHA)
- Signal: Danger Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H301 (51.9%): Toxic if swallowed [Danger Acute toxicity, oral] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 77 reports by companies from 4 notifications to the ECHA C&L Inventory.; Reported as not meeting GHS hazard criteria per 36 of 77 reports by companies.; There are 3 notifications provided by 41 of 77 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- Health Effects: Hypertension, shallow respiration. Dextromethorphan can cause other gastrointestinal disturbances. [Wikipedia] Source: Toxin and Toxin Target Database (T3DB)
- Toxicity Summary: IDENTIFICATION AND USE: Dextromethorphan is a white odorless solid crystal or powder. It is an opium alkaloid derivative, which is found in cough and cold preparations. HUMAN STUDIES: Dextromethorphan is a drug of abuse. The main risks associated with dextromethorphan are ataxia, central nervous system (CNS) stimulation, dizziness, lethargy and psychotic behavior. Less frequently with large doses seizures and respiratory depression can occur. Nausea, vomiting, constipation and tachycardia may also occur. CNS effects include ataxia, drowsiness, vertigo and rarely coma. CNS stimulation may be observed. Restlessness, increased muscle tone with body rigidity have been reported. With extremely large ingestions respiratory depression can occur. Gastrointestinal effects include nausea, vomiting, constipation and dry mouth. Urinary retention may be seen. Dextromethorphan abuse has been described and produces euphoria, CNS stimulation, visual and/or auditory hallucinations. Dextromethorphan hydrobromide is the drug form, thus the possibility of bromide poisoning should be considered in the long term abuser. Dextromethorphan enhances serotonin activity by inhibiting the reuptake of serotonin Source: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: Signs and Symptoms of Overdose; One significant concern regarding dextromethorphan toxicity is its OTC misuse, which has steadily increased since the early 2000s. This misuse is referred to by slang terms such as "going pharming," "robotripping," and "dexing." In 2006, three specific OTC product formulations accounted for 66% of reported dextromethorphan misuse cases in the United States, with Coricidin HBP Cough & Cold Tablets and Robitussin products being prominent. A life-threatening toxicity associated with dextromethorphan abuse is serotonin syndrome, resulting from its serotonin reuptake inhibition properties. When combined with SSRIs or MAOIs, the risk of serotonin syndrome increases significantly. Symptoms include agitation, confusion, dilated pupils, headache, tachycardia, hypotension, high fever, seizures, irregular heartbeat, and may progress to unconsciousness.; Despite the rise in misuse, public health efforts and legislative actions restricting the sale of dextromethorphan-containing products to minors have helped stabilize or reduce abuse rates in recent years. However, continued vigilance is essential to prevent misuse and associated toxicities, given dextromethorph Source: StatPearls
- Toxicity Summary: Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan. Source: Toxin and Toxin Target Database (T3DB)
- Environmental Bioconcentration: The estimated pKa of dextromethorphan is 9.8(1), indicating that dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, bioconcentration in fish is not expected to be an important fate process(SRC). Source: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to be immobile in soil(SRC). The estimated pKa of dextromethorphan is 9.8(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the cation from moist soil is not expected because cations do not volatilize(SRC). Dextromethorphan is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2017). Source: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 9.8(3) indicates dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces and bioconcentration in aquatic organisms are not expected to be an important fate processes(SRC). Dextromethorphan is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(4). Biodegradation data in water were not available(SRC, 2017). Source: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), dextromethorphan, which has an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase dextromethorphan is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 3.3 hours(SRC), calculated from its rate constant of 1.2X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Particulate-phase dextromethorphan may be removed from the air by wet or dry deposition(SRC). Dextromethorphan contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, is expected to be susceptible to direct photolysis by sunlight(SRC). Source: Hazardous Substances Data Bank (HSDB)
- Uses: Antitussive Agents; Excitatory Amino Acid Antagonists Source: Hazardous Substances Data Bank (HSDB)
- Uses: Probe to determine cytochrome 450 phenotype Source: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION Source: Hazardous Substances Data Bank (HSDB)
- Uses: Dextromethorphan (DXM) is an over-the-counter (OTC) cough suppressant commonly found in cold medications. DXM is often abused in high doses by adolescents to generate euphoria and visual and auditory hallucinations. Illicit use of DXM is referred to on the street as "Robo-tripping" or "skittling." These terms are derived from the most commonly abused products, Robitussin and Coricidin. Source: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 38000; Consumption (g per capita; approx.) in Germany (2009): 0.0122; Consumption (g per capita) in the USA (2002): 0.135; Excretion rate: 0.25; Calculated removal (%): 45.3 Source: NORMAN Suspect List Exchange
- Uses: The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (as commonly accompanies the common cold), as well as those resulting from inhaled irritants. In addition, a combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. Source: Toxin and Toxin Target Database (T3DB)
Mis en correspondance par: Existing checksum-valid CAS to unique PubChem CID match. Récupéré le: 2026-08-31. Ouvrir la fiche source
Les classifications scientifiques et les annotations de danger apportent du contexte et ne remplacent pas la décision réglementaire propre au marché indiquée ci-dessus.
Couverture des sources complémentaires et état des correspondances
| Source | Résultat | Vérifié |
|---|---|---|
| NIH PubChem PUG-View | Correspondance exacte | 2026-08-31 |
Une absence de correspondance enregistrée est une preuve utile que la source a été vérifiée ; ce n’est pas l’affirmation que la substance n’existe pas ailleurs.
Récupéré depuis NIH PubChem le 2026-08-31 par correspondance CAS à somme de contrôle valide. Les propriétés chimiques ne remplacent pas la décision réglementaire de cette page.
Source officielle et provenance
- Source enregistrée
- Brazil ANVISA consolidated prohibited substances — RDC 529/2021 through RDC 1.030/2026
- Référence de la source
- RDC 529/2021 consolidated annex, entry 226 (through RDC 1.030/2026)
- Identifiant de la fiche source
annex:226- Version de la source
- RDC 529/2021 consolidated through RDC 1.030/2026
- Langue de la source
- Portuguese with official English identity where published
- État de la traduction
- Official English translation · Traduction anglaise
- Date d’effet
- 2026-06-15
- Source mise à jour le
- 2026-06-15
- Instantané vérifié le
- 2026-08-31 15:26 UTC
- Méthode de validation
- pdfplumber government baseline + 4 RDC 1.030 exclusions + 15 additions; 1,387 substantive rows
- SHA-256
a212e85540a186a842664fbdd4f351af0b1b4baeeb0c4765b9b52c6ce91c1e84
Notes du jeu de données enregistré
- Couverture du jeu de données
- All 1,387 substantive current prohibited rows after applying RDC 1.030/2026 additions, amendments and exclusions to RDC 529/2021
- Note sur l’autorité
- Binding consolidated prohibited list for personal-hygiene products, cosmetics and perfumes
Place de cette fiche dans le jeu de données du marché
Répartition des statuts
Un texte de conditions est présent pour 1387 des 1387 fiches actuelles. Un champ de conditions vide est interprété selon le type de fiche ci-dessus ; il n’est jamais converti en une affirmation d’utilisation sans restriction.
Brazil contexte du marché
Complete prohibited dataset plus current restricted-list workflow
Version de la couverture : ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
All 1,387 substantive current prohibited rows in RDC 529/2021 consolidated through RDC 1.030/2026, plus the current RDC 1.029 restricted-list and identity workflow.
Liste de contrôle de vérification
- Resolve Portuguese, INCI and CAS identity with the ANVISA crosswalk.
- Check the consolidated prohibited list including RDC 1.030/2026 changes.
- Apply RDC 1.029/2026 restrictions and the still-effective complementary rules.
- Verify Mercosur incorporation, regularisation, labelling and transition periods.
Sources officielles du marché
- Brazil ANVISA INCI translation panelIdentity and labelling crosswalk only; regulatory lists must be sourced separately
- Brazil ANVISA restricted substances — RDC 1.029/2026Binding ANVISA resolution effective on publication; replaced RDC 530/2021 for this list part
- Brazil ANVISA consolidated prohibited substances — RDC 529/2021 through RDC 1.030/2026Binding consolidated prohibited list for personal-hygiene products, cosmetics and perfumes
Procédure de vérification et exhaustivité de la fiche
Avant d’utiliser ce résultat dans une décision de conformité
- Confirmez que « Dextrometorfano* e seus sais » et chaque identifiant CAS/CE correspondent à la matière de votre spécification fournisseur.
- Resolve Portuguese, INCI and CAS identity with the ANVISA crosswalk.
- Check the consolidated prohibited list including RDC 1.030/2026 changes.
- Apply RDC 1.029/2026 restrictions and the still-effective complementary rules.
- Verify Mercosur incorporation, regularisation, labelling and transition periods.
- Consignez la version de la source et revérifiez auprès de l’autorité de réglementation avant la fabrication, la notification ou la mise sur le marché.
Champs disponibles dans cette fiche
- Nom officiel de la substanceDisponible
- CASDisponible
- ECDisponible
- Texte de condition distinctDisponible
- Date d’effetDisponible
- Empreinte de l’instantané et méthodeDisponible
Questions auxquelles cette page répond
Citation stable
Dextrometorfano* e seus sais. RDC 529/2021 consolidated annex, entry 226 (through RDC 1.030/2026). Brazil. Source version RDC 529/2021 consolidated through RDC 1.030/2026. CosIng Checker regulatory record: https://cosingchecker.com/fr/regulations/br/records/13432/
Citez l’autorité de réglementation comme autorité juridique. Cette page est un index structuré de preuves et une aide à la vérification, et non un substitut au texte officiel ni à une évaluation juridique professionnelle.
Interprétation et limites pour Brazil
This official record identifies the substance as prohibited for cosmetic use in the stated market scope.
Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.
Comment interpréter le rôle juridique
The cited row forms part of a binding rule or legally incorporated list for this market.
Preuves sur cette page
- Résultat enregistré : Prohibited
- Rôle juridique : Binding rule
- Version de la source : RDC 529/2021 consolidated through RDC 1.030/2026
- Date d’effet : 2026-06-15
Ce que cela ne prouve pas
RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
Recherche complémentaire sur la substance auprès de sources faisant autorité
Aucune de ces sources ne prévaut sur la décision de marché ci-dessus.
Cosmetic Ingredient Review safety assessments
Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents
Independent expert review considered by FDA; not a government approval or binding market rule
Rechercher cette identité à la sourceFDA Global Substance Registration System
UNII identifiers, preferred names, substance types, codes and public substance relationships
Identity registry only; UNII availability does not imply FDA review or approval
Rechercher cette identité à la sourceILO/WHO International Chemical Safety Cards
Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals
International occupational chemical-safety reference; not cosmetic-use approval
Rechercher cette identité à la sourceJapan NITE-CHRIP
Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information
Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules
Rechercher cette identité à la sourceNIOSH Pocket Guide to Chemical Hazards
REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals
US occupational-health guidance and limits; not a cosmetic ingredient decision
Rechercher cette identité à la sourceOECD eChemPortal
Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records
Discovery gateway; each linked authority remains responsible for its data
Rechercher cette identité à la sourceUS EPA CompTox CTX APIs
Clé d’API requise pour l’importDTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data
Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality
Rechercher cette identité à la source